# Melinta Therapeutics, Inc. clinical trials: 32 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 32 trials with Melinta Therapeutics, Inc. as lead sponsor, 0 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Melinta Therapeutics, Inc.: 32 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/melinta-therapeutics-inc

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 32
- Recruiting or not yet: 0
- Read on: November 19, 2026

## Trials

The 25 newest of 32, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| September 25, 2024 | NCT06612255 | A Study Comparing the Bioavailability of a Taste-masked Delafloxacin Powder for Oral Suspension With the Delafloxacin Tablet in Healthy... | Melinta Therapeutics, Inc. | Phase 1 | Terminated | Healthy | 16 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06612255) |
| March 14, 2019 | NCT03873987 | Relative Exposure and Safety Study of Kimyrsa in ABSSSI Patients | Melinta Therapeutics, Inc. | Phase 1 | Completed | Acute Bacterial Skin and Skin Structure Infection | 102 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03873987) |
| May 23, 2018 | NCT03534622 | Evaluate Safety and Pharmacokinetic To Assess Bronchopulmonary Disposition of Intravenous Delafloxacin in Healthy Adults | Melinta Therapeutics, Inc. | Phase 1 | Completed | Pneumonia | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03534622) |
| May 18, 2017 | NCT03159403 | A Retrospective Observational Study to Evaluate the Utilization, Outcomes, and Adverse Events in Participants Treated With Orbactiv®... | Melinta Therapeutics, Inc. | Observational | Completed | Gram-Positive Bacterial Infections | 325 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03159403) |
| December 30, 2016 | NCT03006679 | A Study of Meropenem-Vaborbactam Versus Piperacillin/Tazobactam in Participants With Hospital-Acquired and Ventilator-Associated Bacterial... | Melinta Therapeutics, Inc. | Phase 3 | Withdrawn | Hospital-Acquired Bacterial Pneumonia, Ventilator-Associated Bacterial Pneumonia, Hospital-Acquired Pneumonia... | 0 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03006679) |
| February 10, 2016 | NCT02679573 | Study to Compare Delafloxacin to Moxifloxacin for the Treatment of Adults With Community-acquired Bacterial Pneumonia | Melinta Therapeutics, Inc. | Phase 3 | Completed | Community Acquired Bacterial Pneumonia | 860 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02679573) |
| November 16, 2015 | NCT02605122 | Safety and Efficacy of Solithromycin in Adolescents and Children With Community-Acquired Bacterial Pneumonia | Melinta Therapeutics, Inc. | Phase 2/3 | Terminated | Community-acquired Bacterial Pneumonia | 97 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02605122) |
| July 29, 2015 | NCT02510599 | Safety and Efficacy of Solithromycin in the Treatment of Nonalcoholic Steatohepatitis Without Cirrhosis | Melinta Therapeutics, Inc. | Phase 2 | Completed | Nonalcoholic Steatohepatitis | 10 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02510599) |
| July 22, 2015 | NCT02505997 | Study to Evaluate the Effect of Delafloxacin on the Pharmacokinetics of Midazolam in Healthy Subjects | Melinta Therapeutics, Inc. | Phase 1 | Completed | VA Drug Interactions | 22 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02505997) |
| June 12, 2015 | NCT02470702 | Multiple Oritavancin Doses on Safety, Tolerability, and Pharmacokinetics in Healthy Subjects | Melinta Therapeutics, Inc. | Phase 1 | Completed | Healthy | 14 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02470702) |
| February 6, 2015 | NCT02357524 | Oritavancin on the Results of Multiple Coagulation Tests in Healthy Volunteers | Melinta Therapeutics, Inc. | Phase 1 | Completed | Healthy Volunteers | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02357524) |
| January 19, 2015 | NCT02340988 | Drug-Drug Interaction Potential of Orbactiv (Oritavancin) Co-Administered With Warfarin in Healthy Subjects | Melinta Therapeutics, Inc. | Phase 1 | Completed | Healthy | 36 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02340988) |
| October 20, 2014 | NCT02268279 | Pharmacokinetics and Safety of Solithromycin in Adolescents and Children | Melinta Therapeutics, Inc. | Phase 1 | Completed | Bacterial Infection | 84 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02268279) |
| September 19, 2014 | NCT02245243 | Pharmacokinetics of Delafloxacin in Subjects With and Without Hepatic Impairment | Melinta Therapeutics, Inc. | Phase 1 | Completed | Hepatic Impairment | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02245243) |
| August 6, 2014 | NCT02210325 | Efficacy and Safety Study of Oral Solithromycin Compared to Intramuscular Ceftriaxone Plus Oral Azithromycin in the Treatment of Patients... | Melinta Therapeutics, Inc. | Phase 3 | Completed | Uncomplicated Urogenital Gonorrhea | 264 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02210325) |
| June 18, 2014 | NCT02166476 | Efficacy/Safety of Meropenem-Vaborbactam Compared to Piperacillin-Tazobactam in Adults With cUTI and AP | Melinta Therapeutics, Inc. | Phase 3 | Completed | Urinary Tract Infection Complicated, Acute Pyelonephritis | 550 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02166476) |
| December 19, 2013 | NCT02015637 | Comparison of Delafloxacin Versus Ceftriaxone for the Treatment of Uncomplicated Gonorrhea | Melinta Therapeutics, Inc. | Phase 3 | Terminated | Gonorrhea | 460 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02015637) |
| November 15, 2013 | NCT01984684 | Delafloxacin vs Vancomycin and Aztreonam for the Treatment of Acute Bacterial Skin and Skin Structure Infections | Melinta Therapeutics, Inc. | Phase 3 | Completed | Skin and Subcutaneous Tissue Bacterial Infections, Skin Structures and Soft Tissue Infections | 850 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01984684) |
| October 24, 2013 | NCT01968733 | Efficacy and Safety Study of Intravenous to Oral Solithromycin (CEM-101) Compared to Intravenous to Oral Moxifloxacin in Treatment of... | Melinta Therapeutics, Inc. | Phase 3 | Completed | Community-acquired Bacterial Pneumonia | 863 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01968733) |
| October 21, 2013 | NCT01966055 | Pharmacokinetics and Safety of Solithromycin Capsules in Adolescents | Melinta Therapeutics, Inc. | Phase 1 | Completed | Bacterial Infections | 13 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01966055) |
| March 15, 2013 | NCT01811732 | Delafloxacin Versus Vancomycin and Aztreonam for the Treatment of Acute Bacterial Skin and Skin Structure Infections | Melinta Therapeutics, Inc. | Phase 3 | Completed | Skin and Subcutaneous Tissue Bacterial Infections | 660 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01811732) |
| February 6, 2013 | NCT01784536 | Open Label Study Evaluating the Effects of a Single Oritavancin Infusion on Cytochrome P450 in Healthy Volunteers | Melinta Therapeutics, Inc. | Phase 1 | Completed | Healthy | 16 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01784536) |
| January 8, 2013 | NCT01762839 | A Study to Assess the Cardiac Safety of Oritavancin in Healthy Participants | Melinta Therapeutics, Inc. | Phase 1 | Completed | Healthy | 150 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01762839) |
| December 25, 2012 | NCT01756339 | Efficacy and Safety Study of Oral Solithromycin (CEM-101) Compared to Oral Moxifloxacin in Treatment of Patients With Community-Acquired... | Melinta Therapeutics, Inc. | Phase 3 | Completed | Community-acquired Bacterial Pneumonia | 860 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01756339) |
| May 4, 2012 | NCT01591447 | Safety and Efficacy Study of Single-Dose Oral CEM-101 in Patients With Uncomplicated Urogenital Gonorrhea | Melinta Therapeutics, Inc. | Phase 2 | Completed | Uncomplicated Urogenital Gonorrhea | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01591447) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 12 |
| Phase 2 | 7 |
| Phase 2/3 | 1 |
| Phase 3 | 11 |
| Observational | 1 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 28 |
| Terminated | 3 |
| Withdrawn | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Pneumonia | 5 |
| Bacterial Infections | 5 |
| Skin Diseases, Bacterial | 4 |
| Abscess | 3 |
| Cellulitis | 3 |
| Staphylococcal Skin Infections | 2 |
| Wound Infection | 2 |
| Infections | 2 |
| Gonorrhea | 2 |
| Community-Acquired Pneumonia | 1 |
| Skin Diseases, Infectious | 1 |
| Streptococcal Infections | 1 |
| Non-alcoholic Fatty Liver Disease | 1 |
| Liver Diseases | 1 |
| Soft Tissue Infections | 1 |
| Gram-Positive Bacterial Infections | 1 |
| Chlamydia Infections | 1 |
| Healthcare-Associated Pneumonia | 1 |
| Pneumonia, Ventilator-Associated | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Medical sciences schools in the United States](https://specstream.ai/data/businesses/medical-sciences-schools/united-states)
- [Medical supply stores in the United States](https://specstream.ai/data/businesses/medical-supply-stores/united-states)
- [Medical transportation companies in the United States](https://specstream.ai/data/businesses/medical-transportation-companies/united-states)
- [Mental health clinics in the United States](https://specstream.ai/data/businesses/mental-health-clinics/united-states)
- [Metal fabricators in the United States](https://specstream.ai/data/businesses/metal-fabricators/united-states)
- [Metal suppliers in the United States](https://specstream.ai/data/businesses/metal-suppliers/united-states)
